BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million.Read More
BioTime (NYSE MKT, TASE:BTX) has closed a public offering of 7,453,704 common shares, including 972,222 shares in connection with the exercise in full of an underwriters’ over allotment option, at a price of $2.70 a share for gross proceeds of about $20.1-million.Read More
Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday.
“We view BioTime as roughly halfway through a restructuring designed to unlock shareholder value through separation of non-core assets and accelerated development of the company's cell therapy programs in ophthalmetry, aesthetics and orthopedics,” writes analyst Kevin DeGeeter.Read More